Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40077 | 0.91 | MEN1 (0.44) | MEN1KMT2AGFERALDH1A1CYP3A4 | |
| SCHEMBL7438487 | 0.91 | NFE2L2 (0.47) | MEN1KMT2AGFERALDH1A1CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL14343979 | 0.89 | MEN1 (0.43) | MEN1KMT2AGFERALDH1A1CYP3A4 | |
| SCHEMBL3155441 | 0.89 | NFE2L2 (0.50) | MEN1KMT2AGFERALDH1A1CYP3A4 | |
| SCHEMBL14407436 | 0.86 | CYP3A4 (0.52) | MEN1KMT2AGFERALDH1A1CYP3A4 | |
| SCHEMBL1264017 | 0.85 | GBA1 (0.66) | MEN1KMT2AGFERALDH1A1CYP3A4 | |
| SCHEMBL2627277 | 0.85 | MEN1 (0.43) | MEN1KMT2AGFERALDH1A1CYP3A4 | |
| SCHEMBL4040585 | 0.82 | LMNA (0.53) | MEN1KMT2AGFERALDH1A1 | |
| SCHEMBL7926781 | 0.80 | ACHE (0.42) | MEN1KMT2AALDH1A1CYP3A4HTR6 | |
| SCHEMBL7747132 | 0.80 | SPHK1 (0.41) | MEN1KMT2AALDH1A1CYP3A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398689-B2 | Benzopiperidine derivative, preparation method thereof and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-09-03 | — | — | US | disclosed |
| US-20180318284-A1 | BENZOPIPERIDINE DERIVATIVE, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2018-11-08 | — | — | US | disclosed |
| EP-3395809-A1 | BENZOPIPERIDINE DERIVATIVE, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2018-10-31 | — | — | EP | disclosed |
| EP-0691966-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5455252-A | Antiinflammatory agent, immunosuppressant, antiallergen, skin disorders, bronchodilator, analgesic | SYNTEX (U.S.A.) INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1994022852-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318284-A1 | BENZOPIPERIDINE DERIVATIVE, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | CYP19A1, BRCA1, GPER1 | MEN1 2082/4885KMT2A 1798/4885GFER 1876/4885 |
| US-10398689-B2 | Benzopiperidine derivative, preparation method thereof and medical use thereof | CYP19A1, BRCA1, GPER1 | MEN1 2082/4885KMT2A 1798/4885GFER 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.